Former X CEO Linda Yaccarino has been appointed as the head of eMed Population Health, a telehealth startup specializing in GLP-1 drugs for obesity and diabetes, about a month after stepping down from her position.
With extensive experience in advertising, Yaccarino worked to restore advertiser confidence in X during two challenging years under Elon Musk’s leadership. She played a key role in boosting digital revenue and rebuilding trust among advertisers.
In an interview with Reuters, Yaccarino said she led X through significant growth and is now ready for new challenges.
Founded in 2020 and based in Miami, Florida, eMed partners with employers and government payers to manage the use of GLP-1 medications. These drugs are used to treat obesity and diabetes but have limited insurance coverage due to their high costs.
eMed’s platform promises to reduce the costs of weight loss programs by up to 50% and offers live, on-demand care without appointments. The company gained recognition during the pandemic with COVID-19 tests and later expanded into throat infection and urinary tract infection diagnostics, though it has since shifted away from those areas.
Competition in the GLP-1 market is increasing as many telehealth platforms aim to capture a share. However, safety, marketing, and regulatory concerns remain important topics.
Analysts believe Yaccarino’s expertise in digital marketing and advertising will be a major asset for eMed, especially as the industry increasingly moves toward direct-to-consumer models.
Currently, eMed employs between 51 and 200 people and is working to strengthen its position in the market.
